Klotho Neurosciences, Inc. (KLTO) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KLTO SEC filings page.
This page shows Klotho Neurosciences, Inc. (KLTO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Klotho Neurosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Klotho Neurosciences, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Klotho Neurosciences, Inc. reported a net loss of $10.6M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Klotho Neurosciences, Inc. reported an operating loss of $7.1M against $2.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Klotho Neurosciences, Inc. reported -$13.9M in net income in Q1 2026. This represents a decrease of 554.7% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Cash & Balance Sheet
Klotho Neurosciences, Inc. held $10.0M in cash as of Q1 2026; long-term debt is not reported for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Klotho Neurosciences, Inc.'s ROE was -26.9% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 253.1 percentage points from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
Klotho Neurosciences, Inc. invested $321K in research and development in Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
KLTO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $321K | N/A | $271K | $239K | $0 | N/A | $0 | $0 |
| SG&A Expenses | $6.2M+630.6% | N/A | $231K+343.7% | $339K+14397.1% | $850K+9144.2% | N/A | $52K+774.0% | $2K-84.6% |
| Operating Income | -$9.5M-499.4% | N/A | -$1.9M+35.4% | -$1.9M-378.5% | -$1.6M-136.1% | N/A | -$2.9M-2220.2% | -$396K-62.0% |
| Interest Expense | $2K-99.7% | N/A | $1.2M+2520.3% | $1.8M+11583.6% | $554K | N/A | $45K+120.6% | $15K-25.3% |
| Net Income | -$13.9M-554.7% | N/A | -$2.9M+2.2% | -$4.1M-806.3% | -$2.1M-215.0% | N/A | -$3.0M-1953.6% | -$452K-70.8% |
| EPS (Basic) | -$0.15-87.5% | N/A | -$0.05+72.2% | -$0.12-300.0% | -$0.08-100.0% | N/A | -$0.18-1700.0% | -$0.03-50.0% |
| EPS (Diluted) | -$0.15 | N/A | -$0.05 | -$0.12 | -$0.08 | N/A | -$0.18 | -$0.03-50.0% |
| Diluted Shares (Avg) | 94M | N/A | 59M | 34M | 28M | N/A | 17M | 16M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
KLTO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.7M+1899.7% | $9.6M+290.4% | $10.1M+308.8% | $10.8M+227.7% | $3.0M-84.7% | $2.5M+12.1% | $2.5M-95.8% | $3.3M-94.2% |
| Current Assets | $10.9M+1489.6% | $7.3M+4521.8% | $7.8M+4926.7% | $8.5M+754.8% | $688K+8441.9% | $158K+2273.8% | $155K-24.1% | $1000K+286.2% |
| Cash & Equivalents | $10.0M+1667.6% | $7.2M+11159.0% | $7.3M+14243.3% | $8.4M+897.3% | $566K+6928.6% | $64K+2170.0% | $51K-65.2% | $845K+1990.2% |
| Total Liabilities | $8.3M+252.1% | $130K-89.8% | $146K-85.5% | $195K-96.0% | $2.3M-87.8% | $1.3M-51.7% | $1.0M-98.2% | $4.9M-92.3% |
| Current Liabilities | $554K-76.3% | $77K-93.8% | $93K-90.5% | $63K-93.0% | $2.3M-9.5% | $1.2M-23.0% | $982K-41.0% | $899K-33.5% |
| Non-Current Liabilities | $7.7M+70219.9% | $53K+116.5% | $53K+150.0% | $132K-96.7% | $11K-99.9% | $24K-97.6% | $21K-100.0% | $4.0M-93.6% |
| Total Equity | $51.5M+6708.3% | $9.5M+698.4% | $9.9M+579.7% | $10.7M+786.5% | $756K+110.0% | $1.2M+367.8% | $1.5M+109.2% | -$1.6M+74.3% |
| Retained Earnings | -$35.0M-173.3% | -$21.1M-99.9% | -$19.8M-132.9% | -$16.9M-205.1% | -$12.8M-65.6% | -$10.6M-169.2% | -$8.5M-32.0% | -$5.5M+8.4% |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
KLTO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M-219.9% | -$1.3M-35.5% | -$1.1M-1.4% | -$2.0M-116.9% | -$1.6M-6970.2% | -$944K-373.2% | -$1.1M-6053.3% | -$907K-943.7% |
| Stock-Based Compensation | $5.1M+930.8% | N/A | $640K-67.2% | $390K+940.1% | $496K+72.5% | N/A | $2.0M | $38K |
| Investing Cash Flow | -$365K | N/A | N/A | N/A | N/A | $0-100.0% | $0+100.0% | -$1-100.0% |
| Financing Cash Flow | $8.2M+297.0% | $1.1M+15.7% | $5K-98.1% | $9.8M+471.6% | $2.1M+1074.8% | $957K+857.0% | $279K | $1.7M+761.7% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
KLTO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -26.9%+253.1pp | N/A | -29.2%+173.4pp | -38.4% | -280.0%-93.3pp | N/A | -202.6%-182.0pp | N/A |
| Return on Assets | -23.2%+47.7pp | N/A | -28.7%+91.4pp | -37.7%-24.1pp | -70.9%-67.4pp | N/A | -120.1%-119.9pp | -13.7%-13.2pp |
| Current Ratio | 19.74+19.4x | 95.01+94.9x | 83.69+83.5x | 135.74+134.6x | 0.29+0.3x | 0.13+0.1x | 0.160.0x | 1.11+0.9x |
| Debt-to-Equity | 0.16-2.9x | 0.01-1.1x | 0.01-0.7x | 0.02 | 3.11-50.3x | 1.07 | 0.69-81.4x | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Klotho Neurosciences, Inc. KLTO | FY2025 | N/A | -$10.6M | N/A | $56.7M | — |
| Jasper Therapeutics Inc JSPR | FY2025 | N/A | -$76 | N/A | $23.6M | — |
| LAVA Therapeutics N.V. LVTX | FY2024 | $12.0M | -$25.1M | N/A | $45.8M | 53/100 |
| Mersana Therapeutics Inc MRSN | FY2024 | $40.5M | -$69.2M | N/A | $145.4M | 53/100 |
| IGC Pharma Inc IGC | FY2025 | $1.3M | -$7.1M | N/A | $30.0M | 42/100 |
| LakeShore Biopharma Co., Ltd LSB | FY2025 | $85.7M | -$13.9M | -16.3% | $25.8M | 48/100 |
Where Klotho Neurosciences, Inc. Ranks
Frequently Asked Questions
Is Klotho Neurosciences, Inc. profitable?
No, Klotho Neurosciences, Inc. (KLTO) reported a net income of -$10.6M in fiscal year 2025.
What is Klotho Neurosciences, Inc.'s return on equity (ROE)?
Klotho Neurosciences, Inc. (KLTO) has a return on equity of -111.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Klotho Neurosciences, Inc.'s operating cash flow?
Klotho Neurosciences, Inc. (KLTO) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Klotho Neurosciences, Inc.'s total assets?
Klotho Neurosciences, Inc. (KLTO) had $9.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Klotho Neurosciences, Inc. spend on research and development?
Klotho Neurosciences, Inc. (KLTO) invested $634K in research and development during fiscal year 2025.
What is Klotho Neurosciences, Inc.'s current ratio?
Klotho Neurosciences, Inc. (KLTO) had a current ratio of 95.01 as of fiscal year 2025, which is generally considered healthy.
What is Klotho Neurosciences, Inc.'s debt-to-equity ratio?
Klotho Neurosciences, Inc. (KLTO) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Klotho Neurosciences, Inc.'s return on assets (ROA)?
Klotho Neurosciences, Inc. (KLTO) had a return on assets of -110.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Klotho Neurosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Klotho Neurosciences, Inc. (KLTO) held $7.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Klotho Neurosciences, Inc.'s Piotroski F-Score?
Klotho Neurosciences, Inc. (KLTO) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Klotho Neurosciences, Inc.'s earnings high quality?
Klotho Neurosciences, Inc. (KLTO) reported a net loss of $10.6M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Klotho Neurosciences, Inc. cover its interest payments?
Klotho Neurosciences, Inc. (KLTO) reported an operating loss of $7.1M against $2.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.